1. 1100 Limiting factors to appropriate follow-up in cervical cancer screening. (September 2015) Authors: Viguier, J.; Eisinger, F.; Cortot, A.; Touboul, C.; Blay, J.Y.; Greillier, L.; Couraud, S.; Lhomel, C.; Morére, J.F.; Pivot, X. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S164 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 1101 Less cancer screening in the vulnerable population? Results from the EDIFICE 4 survey. (September 2015) Authors: Morere, J.F.; Viguier, J.; Greillier, L.; Touboul, C.; Blay, J.Y.; Couraud, S.; Cortot, A.; Lhomel, C.; Pivot, X.; Eisinger, F. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S164 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 1208 Being cured: What it means and what it takes. (September 2015) Authors: Eisinger, F.; Pivot, X.; Viguier, J.; Touboul, C.; Blay, J.Y.; Cortot, A.; Greillier, L.; Lhomel, C.; Couraud, S.; Morére, J.F. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S174 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 12LBA Biomarker-driven access to crizotinib in ALK, MET or ROS1 positive (+) malignancies in adults and children: The French national AcSe Program. Issue 3 (September 2015) Authors: Vassal, G.; Moro-sibilot, D.; Le Deley, M.C.; Hoog-labouret, N.; Nowak, F.; Jimenez, M.; Tournigand, C.; Houot, R.; Malka, D.; Aparicio, T.; Escudier, B.; Ray-coquard, I.; Godbert, Y.; Taillandier, L.; Bieche, I.; Lantuejoul, S.; Ferretti, G.; Menu, Y.; Blay, J.Y.; Buzyn, A. Journal: European journal of cancer Issue: Volume 51:Issue 3(2015:Feb.) Page Start: S715 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. 209 The sum of gains and losses of genes encoding for protein tyrosine kinase targets predicts response to multi-kinase inhibitor treatment. (September 2015) Authors: Jiang, X.; Pissaloux, D.; De La Fouchardiere, C.; Desseigne, F.; Wang, Q.; Fondrevelle, M.E.; Cassier, P.; Seigne, C.; Perol, D.; Ray-Coquard, I.; Le Cesne, A.; Penel, N.; Tredan, O.; Blay, J.Y. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S30 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. 31LBA MOST – My Own Specific Therapy – A multicenter, randomized, open-label, phase II trial evaluating the clinical benefit of a maintenance treatment targeting tumor molecular alterations in patients with advanced solid tumors: preliminary results from the everolimus and sorafenib cohorts. (September 2015) Authors: Toulmonde, M.; Le Tourneau, C.; Cropet, C.; Italiano, A.; Bertucci, F.; Ray-Coquard, I.; Tredan, O.; Cassier, P.; Seigne, C.; De la Fouchardiere, C.; Flechon, A.; Desseigne, F.; Frappaz, D.; Gomez-Roca, C.A.; Heudel, P.E.; You, B.; Jaouen, L.; Bernardin, M.; Perol, D.; Blay, J.Y. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S725 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. 3400 Management of Desmoid Tumours (DT): A nationwide survey after labeling of 2 expert networks (RRePS and NetSarc). Issue 3 (September 2015) Authors: Penel, N.; Coindre, J.M.; Cesne, A. Le; Italiano, A.; Neuville, A.; Bonvalot, S.; Terrier, P.; Ray-Coquard, I.; Ranchere-Vince, D.; Robin, Y.M.; Isambert, N.; Chevreau, C.; Duffaud, F.; Bertucci, F.; Rios, M.; Toulmonde, M.; Péchoux, C. Le; Guillement, C.; Courréges, J.B.; Blay, J.Y. Journal: European journal of cancer Issue: Volume 51:Issue 3(2015:Feb.) Page Start: S688 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. 3441 Randomized, open-label, multicenter, phase 3 study of eribulin versus dacarbazine in patients with leiomyosarcoma and adipocytic sarcoma: Health-related quality of life results. (September 2015) Authors: Gelderblom, H.; Blay, J.Y.; D'Adamo, D.; Hudgens, S.; Kontoudis, I.; Cesne, A. Le; Schoffski, P. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S702 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. A Ph-Ib study of TRK-950 combined with anti-cancer treatment regimens in patients with advanced solid tumors. (October 2022) Authors: Hanna, D.; Cassier, P.; Alistar, A.; Sharma, S.; Matrana, M.; George, B.; El-Khoueiry, A.B.; Okano, F.; Von Hoff, D.D.; Blay, J.Y. Journal: European journal of cancer Issue: Volume 174(2022)Supplement 1 Page Start: S32 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. A phase I study of the MDM2 inhibitor AMG 232 in patients with advanced p53 wild type (p53WT) solid tumors or multiple myeloma. (December 2016) Authors: Langenberg, M.H.; Gluck, L.; Weger, V.; Frank, R.; Eskens, F.; Blay, J.Y.; Soria, J.C.; Chawla, S.; Gounder, M.; Wagner, A.; Zhang, Y.; Kambuj, P.; Loberg, R.; Henary, H. Journal: European journal of cancer Issue: Volume 69(2016)supplement 1 Page Start: S34 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗